Walleye Trading LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
Walleye Trading LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$727,072
-81.1%
13,958
-80.3%
0.00%
-87.5%
Q1 2023$3,840,210
+2.3%
70,918
-0.1%
0.01%
-27.3%
Q4 2022$3,754,992
-29.7%
70,956
-38.2%
0.01%
-31.2%
Q3 2022$5,338,000
+270.4%
114,734
+354.6%
0.02%
+220.0%
Q2 2022$1,441,000
-4.9%
25,239
+2.0%
0.01%0.0%
Q1 2022$1,515,000
-8.3%
24,755
-21.7%
0.01%
-16.7%
Q4 2021$1,653,000
+17.7%
31,600
-16.2%
0.01%
+20.0%
Q3 2021$1,405,000
-79.8%
37,700
-77.8%
0.01%
-81.5%
Q2 2021$6,943,000
+1850.3%
170,100
+1520.0%
0.03%
+1250.0%
Q1 2021$356,000
-68.9%
10,500
-70.8%
0.00%
-60.0%
Q4 2020$1,143,000
-30.9%
35,958
-44.2%
0.01%
-37.5%
Q3 2020$1,654,000
+499.3%
64,438
+258.9%
0.01%
+300.0%
Q1 2020$276,000
-98.6%
17,955
-96.8%
0.00%
-98.5%
Q4 2019$19,109,000
+4677.2%
556,960
+941.0%
0.13%
+4300.0%
Q3 2019$400,000
-27.9%
53,500
+25.2%
0.00%
-40.0%
Q2 2019$555,000
-18.5%
42,726
-23.6%
0.01%0.0%
Q1 2019$681,000
+202.7%
55,928
+183.7%
0.01%
+400.0%
Q4 2018$225,000
+11150.0%
19,711
+9755.5%
0.00%
Q2 2017$2,0002000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders